Physician profile
Victoria Hatcher
NPI 1235621384
$3,546.41
in general payments reported to CMS, 2019-2025
34 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $496 · 2022: $694 · 2023: $673 · 2024: $1,190 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.27 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $441.82 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $437.54 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $293.28 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $264.87 | 2021-2025 | |
| Amgen INC. | $206.28 | 2023-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $159.88 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $157.40 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.79 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $111.60 | 2021-2024 | Verquvo, Belsomra, Capvaxive |
| Averitas Pharma INC. | $101.66 | 2024 | Qutenza |
| Lilly USA, LLC | $70.17 | 2022-2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.67 | 2023-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $59.69 | 2024 | Veozah |
| Medtronic, INC. | $59.46 | 2025 | Symplicity G3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.73 | 2022-2025 | |
| Esperion Therapeutics, INC. | $47.25 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $43.13 | 2021 | |
| Inspire Medical Systems, INC. | $42.00 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $33.99 | 2024 | |
| Gilead Sciences, INC. | $32.80 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $30.28 | 2024 | Camzyos, Eliquis |
| Corcept Therapeutics | $30.07 | 2021-2022 | |
| Eisai INC. | $29.20 | 2021-2024 | |
| Grifols USA, LLC | $28.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.96 | 2024 | Trintellix |
| Baxter Healthcare | $25.79 | 2022 | |
| Welch Allyn | $25.79 | 2021 | |
| Daiichi Sankyo INC. | $14.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.37 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.95 | 2025 | Caplyta |
| Grt US Holding, INC. | $13.63 | 2021 | |
| Exact Sciences Corporation | $13.18 | 2023 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Hatcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.